Madhya Pradesh Online Journal

Peripheral T-Cell Lymphoma (PTCL) Market to Accelerate Substantially During the Forecast Period – DelveInsight | Key Companies – Eisai, HUYA, Celgene, Onxeo, Solasia, Seattle Genetics, and Others

 Breaking News
  • No posts were found

Peripheral T-Cell Lymphoma (PTCL) Market to Accelerate Substantially During the Forecast Period – DelveInsight | Key Companies – Eisai, HUYA, Celgene, Onxeo, Solasia, Seattle Genetics, and Others

August 12
22:34 2022
Peripheral T-Cell Lymphoma (PTCL) Market to Accelerate Substantially During the Forecast Period - DelveInsight | Key Companies - Eisai, HUYA, Celgene, Onxeo, Solasia, Seattle Genetics, and Others
Delveinsight Business Research LLP
As per DelveInsight, Peripheral T-Cell Lymphoma (PTCL) Market size in the United States was estimated to be USD 616 million in 2017, which is expected to increase during the forecast period owing to the increasing prevalent population of PTCL patients in the 7MM.

DelveInsight’s “Peripheral T-Cell Lymphoma (PTCL) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Peripheral T-Cell Lymphoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Peripheral T-Cell Lymphoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Peripheral T-Cell Lymphoma: An Overview

The peripheral T-cell lymphomas (PTCLs) encompass a heterogeneous group of diseases representing approximately ∼10% to 15% of non-Hodgkin lymphomas. It usually develops from mature-stage white blood cells called T-cells and natural killer (NK) cells. Most PTCL subtypes are aggressive (fast-growing) lymphomas, including PTCL-NOS, AITL, ALCL, enteropathy-type T-cell lymphoma, and extranodal natural killer (NK) cell/T-cell lymphoma.

Peripheral T-cell Lymphoma was classified by WHO in 2008 and updated in 2016. According to this, the Peripheral T-cell Lymphomas can be broadly classified according to the site of origin of the malignant T cell in the body- Nodal, Extranodal, Cutaneous and Leukemic.

Peripheral T-Cell Lymphoma Market Key Facts

  • Based on the United States Surveillance, Epidemiology, and End Results (SEER) Registry, the incidence of PTCL is < 1 case per 100,000 people in the United States. In Europe and North America, T-cell and NK-cell lymphoma account for 5-10% of all cases of NHL.

  • As stated in a study titled “Pathogenesis of Peripheral T Cell Lymphoma” by Marco Pizzi et al., PTCLs typically affects middle-aged to elderly patients. They present as either nodal (60%) or extranodal (40%) lesions.

Peripheral T-Cell Lymphoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Peripheral T-Cell Lymphoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report details the Peripheral T-Cell Lymphoma market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Peripheral T-Cell Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Peripheral T-Cell Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Peripheral T-Cell Lymphoma market or expected to get launched during the study period. The analysis covers Peripheral T-Cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Peripheral T-Cell Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market

Peripheral T-Cell Lymphoma Therapeutics Analysis

With no standard drug treatments available in clinical practice, the response rate of cancer to conventional chemotherapies is low; the tolerance is poor, and relapse often occurs. 

As per DelveInsight, the dynamics of the Peripheral T-cell Lymphoma (PTCL) market are anticipated to change in the coming years owing to the rise in healthcare spending across the world, the increase in R&D activities, and patient awareness about the treatment options.

Some of the key companies in the Peripheral T-Cell Lymphoma (PTCL) Market include:

  • Eisai

  • Onxeo

  • Seattle Genetics

  • Aileron Therapeutics

  • Solasia Pharma 

  • HUYA Bioscience

  • Celgene Corporation

  • Spectrum Pharmaceuticals

  • Kyowa Hakko Kirin Co, Ltd.

And many others. 

Peripheral T-Cell Lymphoma (PTCL) Therapies covered in the report include:

  • Darinaparsin

  • ALRN 6924

  • HBI-8000

  • E7777

  • Adcetris (Brentuximab vedotin)

  • Poteligeo (Mogamulizumab)

  • Folotyn (Pralatrexate)

  • Istodax (Romidepsin)

  • Beleodaq (Belinostat)

And many more.

Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Peripheral T-Cell Lymphoma Competitive Intelligence Analysis

4. Peripheral T-Cell Lymphoma Market Overview at a Glance

5. Peripheral T-Cell Lymphoma Disease Background and Overview

6. Peripheral T-Cell Lymphoma Patient Journey

7. Peripheral T-Cell Lymphoma Epidemiology and Patient Population

8. Peripheral T-Cell Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Peripheral T-Cell Lymphoma Unmet Needs

10. Key Endpoints of Peripheral T-Cell Lymphoma Treatment

11. Peripheral T-Cell Lymphoma Marketed Products

12. Peripheral T-Cell Lymphoma Emerging Therapies

13. Peripheral T-Cell Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. Peripheral T-Cell Lymphoma Market Outlook (7 major markets)

16. Peripheral T-Cell Lymphoma Access and Reimbursement Overview

17. KOL Views on the Peripheral T-Cell Lymphoma Market.

18. Peripheral T-Cell Lymphoma Market Drivers

19. Peripheral T-Cell Lymphoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/peripheral-t-cell-lymphoma-ptcl-market

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

 

Other Trending Healthcare Report by DelveInsight

Spinal Cord Stimulators (SCS) Market
“Spinal Cord Stimulators (SCS) Market” research report provides comprehensive insights into the historic and forecasted market size, share, trends, and growth estimation for Spinal Cord Stimulators. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Spinal Cord Stimulators market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/